Wegovy weight loss results "very encouraging," says Novo EVP
Recently launched weight loss drug Wegovy has reportedly shown an average loss of weight of 15.2 percent over two years in a phase IIIb trial. This is "very encouraging," says EVP Martin Holst Lange.
.jpg)
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
An average weight loss of 15.2 percent over two years. These results come from a phase IIIb study of the obesity drug Wegovy, Novo Nordisk reports in a press release in connection with this year's Obesity Week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Raising ambitions at Novo Nordisk an obvious move, says CEO
For subscribers
.jpg&w=384&q=75)
